Email this article The Effect of Preoperative Oil Chemoembolization Techniques on the Results of Combined Treatment of Operable Pancreatic Cancer
- Authors: Kaprin D.A.1, Tavobilov M.M.2, Tsurkan V.A.2
-
Affiliations:
- City Clinical Hospital named after M.P. Konchalovsky
- S.P. Botkin City Clinical Hospital
- Issue: Vol 16, No 1 (2023)
- Pages: 40-51
- Section: Original articles
- URL: https://journal-vniispk.ru/2070-478X/article/view/146911
- DOI: https://doi.org/10.18499/2070-478X-2023-16-1-40-51
- ID: 146911
Cite item
Full Text
Abstract
Background: Pancreatogastroduodenal resection is widely used for the treatment of pancreatic cancer but the 5-year survival rate does not exceed 10%. The treatment should be combined, but the question of the expediency of neoadjuvant therapy (NAT) with initially operable cancer has not been resolved.
Aims: Substantiation of the expediency of the use of preoperative intra-arterial interventions in the combined treatment of patients with operable pancreatic cancer and the study of the impact of the technical features of the intervention on the treatment results.
Materials and methods: The study included 92 patients (45 men and 47 women; mean age 63.9±10.1 years, T2N0M0 n=13; T3N0M0 n=32; T2N1M0 n=1; T4N0and1M0 n=46) who received combined treatment for the period 2014-2017.In I group, n=45 patients, the NAT was not performed.In II group, n=47 patients underwent intra-arterial oil chemoembolization of the pancreas with an emulsion of oil contrast and gemcitabine concentrate 400 mg/m2.The technique of distributive embolization of the artery gastroepiploica (GEA) differed: in IIA group, n= 22 patients – with a spiral; in IIB group, n=25 patients – with a temporarily inflated balloon.All 92 patients underwent radical surgery and received adjuvant chemotherapy based on gemcitabine 1000 mg/m2 in 1,8.15 days, 6 cycles. The frequency of specific and general postoperative complications was analyzed. For control, ultrasound, CT with contrast, CA 19-9 antigen level, general and biochemical blood tests were used. For 5 years, the results of each patient were tracked. The primary endpoints were overall (OS) and relapse-free (RFS) survival.
Results: Postembolization syndrome did not affect the timing of the operation. The edematous form of acute pancreatitis was noted in 11 (50%) patients of group IIA and in 5 (20%) patients of group IIB, (p=0.043). Destructive pancreatitis was not marked. The overall 1-year survival rate (OS) in I group (n=31) was 68.9%, in II group (n=40) 85.1%, (p=0.062). The 2-years OS was: in I group (n=19) 42.2%, in II group (n=30) 63.8%, (p=0.042). The 3-year OS was: in I group (n=9) 20%, in II group (n=19) 40.4%, (p=0.021). The 4-years OS was: in I group (n=4) 8.9%, in II group (n=7) 14.8%, (p=0.387). The 5-year OS was: in I group 0, in II group (n=2) 4.3%, (p=0.168). The 1-year RFS was: in I group (n=23) 57.1%, in II group (n=29) 61.7%, (p=0.316). The 2-years RFS was: in I group (n=10) 22.2%, in II group (n=23) 48.9%, (p=0.012). The 3-years RFS was: in I group (n=7) 15.6%, in II group (n=16) 34%, (p=0.047). The 4-years RFS was: in I group (n=3) 6.7%, in II group (n=5) 10.6%, (p=0.568). The 5-years RFS was: in I group 0, in II group (n=1) 4%, (p=0.333).
Conclusions: The results of the study confirm the feasibility of using preoperative intra-arterial interventions in the combined treatment of pancreatic cancer. There was a significant difference in the rates of 2-year and 3-year OS and RFS in patients receiving such therapy. The technique of occlusion of the artery gastroepiploica with a balloon probably provides more preferable results.
Full Text
##article.viewOnOriginalSite##About the authors
Dmitriy Andreevich Kaprin
City Clinical Hospital named after M.P. Konchalovsky
Email: kaprind@gmail.com
ORCID iD: 0000-0002-1490-0427
SPIN-code: 1109-5565
Deputy Chief Physician for the long-term development
Russian Federation, Chestnut Alley, 2 p.1, Zelenograd, Moscow, 124489Mikhail Mikhailovich Tavobilov
S.P. Botkin City Clinical Hospital
Email: botkintmm@yandex.ru
ORCID iD: 0000-0003-0335-1204
SPIN-code: 9554-5553
Head of the Department of Hepatopancreatobiliary Surgery № 50 and Oncosurgical Department № 73 of the State Medical University named after S.P. Botkin DZM
Russian Federation, 5, 2nd Botkinsky Ave., Moscow, 125284Vladimir Andreevich Tsurkan
S.P. Botkin City Clinical Hospital
Author for correspondence.
Email: i@tsurkan-top.ru
ORCID iD: 0000-0001-5176-9061
SPIN-code: 5378-2801
radiologist of the State Medical University named after S.P. Botkin DZM
Russian Federation, 5, 2nd Botkinsky Ave., Moscow, 125284References
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. doi: 10.3322/caac.21654.
- Tsimmerman YaS. Pancreatic cancer: Terra incognita of modern gastroenterology. Vestn. kluba pankreatologov. 2016; 3: 8-16. (in Russ.)
- Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021; 5. doi: 10.1002/ijc.33588.
- Andersson R, Haglund C, Seppänen H, Ansari D. Pancreatic cancer - the past, the present, and the future. Scand J Gastroenterol. 2022;57(10):1169-1177. doi: 10.1080/00365521.2022.2067786.
- Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019;14(1):141. doi: 10.1186/s13014-019-1345-6. PMID: 31395068; PMCID: PMC6688256
- Strobel O, Buchler MW. Evolution of Surgery for Pancreatic Cancer and Future Directions. Textbook of Pancreatic Cancer: Principles and Practice of Surgical Oncology. Cham: Springer International Publishing. 2021; 999-1015
- Delpero JR, Bachellier P, Regenet N, Le Treut YP, Paye F, Carrere N, Sauvanet A, Autret A, Turrini O, Monges-Ranchin G, Boher JM. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford). 2014;16(1):20-33. doi: 10.1111/hpb.12061.
- Shabunin AV, Karpov DA, Kizhaev EV. Combined surgical treatment of patients with pancreatic head cancer. Annaly khirurgicheskoi gepatologii. 2018; 23: 8-13. (in Russ.)
- Moskvicheva LI, Bolotina LV. Possibilities of chemotherapy in patients with locally advanced and metastatic adenogenic pancreatic cancer. Issledovaniya i praktika v meditsine. 2020; 7: 4: 118-134.(in Russ.)
- Birrer DL, Golcher H, Casadei R, Haile SR, Fritsch R, Hussung S, Brunner TB, Fietkau R, Meyer T, Grützmann R, Merkel S, Ricci C, Ingaldi C, Di Marco M, Guido A, Serra C, Minni F, Pestalozzi B, Petrowsky H, DeOliveira M, Bechstein WO, Bruns CJ, Oberkofler CE, Puhan M, Lesurtel M, Heinrich S, Clavien PA. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Ann Surg. 2021;274 (5):713-720. doi: 10.1097/SLA.0000000000005126.
- Schneider M. Commentary: Neoadjuvant treatment of resectable pancreatic cancer: Lack of level III evidence. Surgery. 2020;168:6:1015-1016.
- Polikarpov AA, Pavlovskii AV, Gulo AS. Long-term results of combined X-ray endovascular and surgical treatment of patients with ductal adenocarcinoma of the pancreas. Vestnik khirurgii. 2013; 122 (4): 40–43. (in Russ.)
- Kozlov AV, Tarazov PG, Korytova LI, Polikarpov AA, Vasil'ev GL, Popov SA. Sposob lecheniya mestnorasprostranennogo neoperabel'nogo raka podzheludochnoi zhelezy: pat. 2528881 Ros. Federatsiya: MPK 7 A61K31/198, A61K31/282, A61R35/00, A61N5/00 Ros. nauch. tsentr radiol. i khirurg. tekhnologii. № 2013121081/15; zayavl. 07.05.13; opubl. 20.09.14.(in Russ.)
- Tavobilov MM, Karpov AA, The use of neoadjuvant regional chemotherapy in patients with pancreatic head cancer. Moskovskii khirurgicheskii zhurnal. 2016; 4: 50: 65-70. (in Russ.)
- Pavlovskii AV, Granov DA, Tarazov PG. Oil radiopaque chemoembolization in the combined treatment of patients with operable pancreatic head cancer. Evraziiskii onkologicheskii zhurnal. 2020; 8: 2:622. (in Russ.)
- Pavlovskii AV. Oil chemoembolization of pancreatic arteries in locally advanced cancer. Prakticheskaya onkologiya. 2004; 5:2(18): 108-114. (in Russ.)
- Granov DA, Pavlovskii AV, Tarazov PG. Oil arterial chemoembolization: a new method of pancreatic cancer therapy. Vopr. onkologii. 2003; 49:5: 579-584. (in Russ.)
- Dolgushin BI. Interventsionnaya radiologiya v onkologii: Natsional'noe rukovodstvo v 3-kh tomakh. M.: Izdatel'skii dom Vidar-M. 2022; 783. (in Russ.)
- Kozlov AV, Tarazov PG, Korytova LI, Polikarpov AA, Vasil'ev GL, Popov SA. Sposob lecheniya mestnorasprostranennogo neoperabel'nogo raka podzheludochnoi zhelezy: pat. 2528881 Ros. Federatsiya: MPK 7 A61K31/198, A61K31/282, A61R35/00, A61N5/00. zayavitel' i pravoobladatel' Ros. nauch. tsentr radiol. i khirurg. tekhnologii. № 2013121081/15; zayavl. 07.05.13; opubl. 20.09.14. (in Russ.)
- Khairutdinov ER, Tsurkan VA, Arablinskii AA. Sposob selektivnoi khimioembolizatsii zlokachestvennykh opukholei podzheludochnoi zhelezy: patent RU 2624323 C1. Moskva. 2017.(in Russ.)
- Pavlovskii AV, Tarazov PG, Granov DA. Sposob lecheniya zlokachestvennykh opukholei podzheludochnoi zhelezy. Patent na izobretenie №2156137 ot 20.09.2000. (in Russ.)
Supplementary files
